Pacritinib clinical trials
Pacritinib is named as an intervention in 7 current clinical trials in our UK, USA, Spain, France, Italy, Canada, Germany, Japan, Netherlands, Belgium, Poland, Czechia, South Korea, Israel, Denmark, Taiwan, India, Brazil, Australia and Singapore registers. 4 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Swedish Orphan Biovitrum (2). The most-studied condition is Myelofibrosis.
Where Pacritinib is approved
All regulators →Of the three regulators tracked here, the first to approve Pacritinib was the US, on 28 Feb 2022.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Pacritinib patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Pacritinib, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 3 listed patents; the last listed expires 25 Mar 2030 (US 8980873).
- Latest patent on the drug substance itself: 25 Mar 2030 (US 8980873).
- Exclusivity ODE-397: Orphan drug exclusivity: treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential …, until 28 Feb 2029.
- Exclusivity NCE: New chemical entity, until 28 Feb 2027.
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Pacritinib
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Pacritinib works
All drug targets →- Tyrosine-protein kinase JAK2 inhibitor InhibitorTarget: JAK2 Janus kinase 2✓ In ChEMBL and the Guide to Pharmacology
- Tyrosine-protein kinase receptor FLT3 inhibitor InhibitorTarget: FLT3 fms related receptor tyrosine kinase 3✓ In ChEMBL and the Guide to Pharmacology
- Activin receptor type-1 inhibitor InhibitorTarget: ACVR1 activin A receptor type 1ChEMBL only
- Interleukin-1 receptor-associated kinase 1 inhibitor InhibitorTarget: IRAK1 interleukin 1 receptor associated kinase 1ChEMBL only
- Primary myelofibrosisPhase 3
- B-cell chronic lymphocytic leukemiaPhase 2
- COVID-19Phase 2
- Hodgkins lymphomaPhase 2
- Immunoblastic LymphadenopathyPhase 2
- Sezary syndromePhase 2
- ThrombocytopeniaPhase 2
- VEXAS syndromePhase 2
- Waldenstrom macroglobulinemiaPhase 2
- Acute lymphoblastic leukemiaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL2035187, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7793, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Pacritinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Pacritinib
- ChEMBL
- CHEMBL2035187
- DrugBank
- DB11697
- PubChem CID
- 46216796
- CAS number
- 937272-79-2
- FDA UNII
- G22N65IL3O
- Wikidata
- Q3888693
- Wikipedia
- Pacritinib
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Pacritinib
7 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Pacritinib
11 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Swedish Orphan Biovitrum | 2 |
| Theradex | 1 |
| Karyopharm Therapeutics Inc | 1 |
| Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas | 1 |
| Stichting Hemato-Oncologie voor Volwassenen Nederland | 1 |
| National University Hospital, Singapore | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Pacritinib trials
How many clinical trials are testing Pacritinib?
7 current trials in our UK, USA, Spain, France, Italy, Canada, Germany, Japan, Netherlands, Belgium, Poland, Czechia, South Korea, Israel, Denmark, Taiwan, India, Brazil, Australia and Singapore registers name Pacritinib as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Pacritinib trials recruiting patients?
Yes. 4 of the 7 trials are recruiting: 3 with sites in UK, 3 with sites in USA, 3 with sites in Spain, 2 with sites in France, 2 with sites in Italy, 2 with sites in Canada, 2 with sites in Germany, 1 with sites in Japan, 1 with sites in Netherlands, 1 with sites in Belgium, 1 with sites in Poland, 1 with sites in Czechia, 1 with sites in South Korea, 1 with sites in Israel, 1 with sites in Denmark and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Pacritinib clinical trials?
Swedish Orphan Biovitrum (2), Theradex (1), Karyopharm Therapeutics Inc (1) and Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Pacritinib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Pacritinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pacritinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.